Investing.com - ADMA Biologics Inc (NASDAQ: ADMA) reported second quarter EPS of $0.1300, $0.05 better than the analyst estimate of $0.0800. Revenue for the quarter came in at $107.2M versus the consensus estimate of $86.44M.
Guidance
ADMA Biologics Inc sees FY 2024 revenue of $400.0000M-$445.0000M versus the analyst consensus of $357.5000M.
ADMA Biologics Inc's stock price closed at $12.19. It is up 38.3700% in the last 3 months and up 200.1200% in the last 12 months.
ADMA Biologics Inc saw 1 positive EPS revisions and 0 negative EPS revisions in the last 90 days. See ADMA Biologics Inc's stock price’s past reactions to earnings here.
According to InvestingPro, ADMA Biologics Inc's Financial Health score is "great performance".
Check out ADMA Biologics Inc's recent earnings performance, and ADMA Biologics Inc's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar